Beam Therapeutics Inc expected to post a loss of $1.13 a share - Earnings Preview

Beam Therapeutics

02/08/2024 15:59

* Beam Therapeutics Inc  BEAM.OQ   BEAM.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 6
(estimated) for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 29.5% decrease in revenue to $14.183 million from $20.12
million a year ago, according to the mean estimate from 14
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Beam Therapeutics Inc is
for a
loss of $1.13 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $56.00​, above​ its last closing price of $30.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.36       -1.42      -1.21     Beat    14.6
 Dec. 31 0001  -0.89       -1.01      1.73      Beat    271.1
 Sep. 30 2023  -1.32       -1.36      -1.08     Beat    10.4​
 Jun. 30 2023  -1.46       -1.42      -1.08     Beat    24.2
 ​​Mar.        -1.34       -1.34      -1.33     Beat    0.9
 31 2023                                                
 Dec. 31 2022  -1.40       -1.33      -0.54     Beat    59.3​
 Jan. 1 0001   -1.10       -1.31      -1.56     Missed  -18.8
 Jun. 30 2022  -1.10       -1.08      -1.02     Beat    5.4
 This summary was machine generated August 2 at 14:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)